Everyone who's ever applied for a job fears that recruiters will glance at their resumes and toss them out. Apparently, Pfizer's Swedish operation feared the same thing--and it tossed out the whole process.
In the midst of an ongoing campaign to boost its profile in the increasingly crowded animal health space, Parnell Pharmaceutical Holdings named two new top executives and one board member to its growing team on Tuesday evening. The Kansas company appointed veterinarian Edward Robb as chief scientific officer and Andy Ferrigno as vice president of global sales. Thomas E. Duley of life science consultancy King & Spalding was named to the company's board of directors.
Julie Gerberding, president of Merck's vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday.
BioClinica has named John Hubbard as its new CEO. Hubbard joins the company from Pfizer, where he worked as senior vice president and worldwide head of development operations.
Sanofi Chairman Serge Weinberg, who must replace Chris Viehbacher after ousting the outspoken CEO, has publicly expressed his own exasperation with France, saying its high taxes have made it hard to attract talent.
Weakening sales in Sanofi's U.S. diabetes franchise are not only hammering its top line, they're roughing up its executives ranks. Shortly after former CEO Chris Viehbacher got canned, in part, for an unexpected announcement about how diabetes drug sales would be soft next year, a vice president of sales in the U.S. left Sanofi.
Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...
Teva, whose board composition has stirred up some recent shareholder activism, has picked its next chairman. And investors pushing for more experienced leadership may be pleased with his resume.
Just a few months after Ron Renaud completed the sale of Idenix to Merck for $3.85 billion, the biotech CEO's vacation is officially over. Instead, he's opening a new chapter in his career--taking the helm at the upstart RaNA in Cambridge, MA, and switching focus from hepatitis C to long noncoding RNA.
When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers.